Colorectal Cancer Screening Follow-Up Crucial to Saving Lives

Recent updates to the American Cancer Society’s colorectal cancer (CRC) screening guidelines represent meaningful progress in expanding access to early detection: https://lnkd.in/gK3fpmCc By including additional blood- and stool-based screening options, these guidelines have the potential to lower barriers and bring more people into the colorectal cancer screening pathway—an important step forward in closing the screening gap. But it’s critical to recognize an equally important truth: for many patients, these non-invasive options are just the first step. An abnormal result from a blood- or stool-based test should be followed by a diagnostic colonoscopy to confirm findings and enable timely intervention. Without that follow-through, we risk missing the opportunity to detect and treat colorectal cancer when outcomes are most favorable. Colorectal cancer is one of the most preventable and treatable cancers when detected early. That’s why our focus must remain on the full continuum of care: ✅ Expanding access to screening ✅ Increasing participation ✅ Ensuring timely follow-up As a medical community, we have an opportunity and a responsibility to strengthen each step of this pathway and help more patients benefit from early detection. Olympus Corporation

The FDA has approved zidesamtinib (Jideytro) for patients with advanced ROS1-positive non-small cell lung cancer who have stopped responding to other drugs aimed at ROS1. Dr. Alexander Drilon, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), led the clinical trial that resulted in zidesamtinib’s approval. Overall, 44% of patients responded to the drug, and after one year, 69% of responding patients were still responding. Zidesamtinib was designed to work in patients whose tumors have learned to get around older drugs. It can also penetrate the blood-brain barrier, making it effective at attacking cancer cells that have spread to the brain, a common site of metastasis for lung cancer. “This was the most precisely targeted ROS1 inhibitor that science could create, while decreasing side effects at the same time,” says Dr. Drilon. “The results have been really good for many patients.” The FDA’s approval means that zidesamtinib will be available to patients throughout the United States, whether or not they have access to a clinical trial. Learn more about the MSK research behind the approval: https://bit.ly/44YpQeJ

NON-SMALL CELL LUNG CANCER — US NSCLC splits into five biomarker-defined segments, and 51% of US patients are diagnosed only after the disease reaches distant stage. Non-small cell lung cancer is not one disease to size. Adenocarcinoma accounts for roughly 40% of all lung cancers, squamous cell carcinoma for 25 to 30%, and large cell carcinoma for about 10%. Within that histology map sits the segmentation that actually drives treatment: EGFR, ALK, ROS1, KRAS G12C, and PD-L1 expression tier, each carrying a different first-line standard of care, and sizing the wrong one is the most common pre-launch error. The US will see an estimated 229,410 new lung cancer diagnoses in 2026, and non-small cell histology accounts for roughly 85% of them. Fifty-one percent of cases present at distant stage against just 24% localized, based on SEER 2016-2022 diagnosis data, and the biomarker-driven segment map only helps a patient whose disease is caught before it reaches that point. EGFR, ALK, KRAS G12C, and PD-L1 prevalence vary meaningfully across US and North American cohorts, and the diagnosis-to-treatment pathway loses patients between tissue-NGS or liquid-biopsy testing and the point first-line therapy actually starts, with turnaround time and guideline-complete testing rate the two levers that matter most for commercial modelling. Sizing the wrong biomarker segment is the most common pre-launch NSCLC error. Five questions this report answers: Q1 - How does NSCLC segment by histology and actionable biomarker, and what governs treatment choice in each? Q2 - How many patients present early enough for that segmentation to matter? Q3 - What share of NSCLC actually carries each actionable biomarker? Q4 - Which US centers and trial networks define practice and generate the evidence base? Q5 - Where does the diagnosis-to-treatment pathway lose patients, and how fast does it move? Share your commercial question with us. We'll align on scope — then build the right intelligence around it. → moatrx.com/axlrx.html #NSCLC #LungCancer #Biomarkers #PrecisionOncology #DiseaseLandscape #USMarket Live report page: https://lnkd.in/dS2SWkdH

A new milestone for cancer immunotherapy The FDA has granted accelerated approval to Tudriqev™ (an oncolytic virus) in combination with nivolumab for patients with advanced melanoma whose disease has progressed following anti-PD-1 therapy. This approval represents an important step forward for patients with limited treatment options and further validates the growing role of innate immune activation in cancer immunotherapy. Oncolytic viruses are designed to selectively infect tumors, trigger local immune activation, and promote systemic anti-tumor immune responses. Together with other emerging approaches—including TLR agonists-these strategies aim to convert immunologically "cold" tumors into tumors that can be recognized and attacked by the immune system. At MonTa Biosciences, we are encouraged to see continued progress in developing innovative immunotherapies for patients with melanoma and other solid tumors, and further supports our ongoing clinical phase IB study in cutaneous and uveal melanoma patients that has relapsed after immunotherapy. Congratulations to the melanoma patients that will benefit from treatment and everyone involved in advancing new treatment options for patients. #Melanoma #Immunotherapy #CancerResearch #InnateImmunity #Oncology #Innovation #cancer

Lets today celebrate the FDA accelerated approval of a new intratumoral oncolytic virus in cutaneous melanoma patients that no longer benefit from checkpoint therapy. Congratulations to the patients and their relatives, and the team involved. The response rate demonstrated was approximately 24%, which is a significant win for these patients that have poor options for treatment, but also means there is still an unmet medical need for the remaining 76% of patients. #Melanoma #Immunotherapy #CancerResearch #Microbiome #CancerScience #Innovation

A new era in cancer treatment has officially begun. The FDA has approved Tumor-Infiltrating Lymphocyte (TIL) Therapy for patients with advanced melanoma. This isn't just another cancer drug. It's a completely different way of fighting cancer. Here's how it works: Doctors collect T cells directly from the patient's tumor. These naturally cancer-fighting immune cells are multiplied in the laboratory from thousands to billions. The expanded cells are then infused back into the patient, giving the immune system a much stronger army to attack cancer. Why is this such a breakthrough? Because these T cells have already recognized the cancer. They don't need to be taught what to attack. They simply need reinforcements. This makes TIL therapy one of the most personalized forms of immunotherapy available today. And this is only the beginning. Researchers are already studying TIL therapy for other cancers, including: • Breast cancer • Cervical cancer • Lung cancer • Ovarian cancer • Several solid tumors If these trials continue to succeed, personalized cell therapy could redefine cancer treatment over the next decade. Every major medical breakthrough starts with one approval. Today, melanoma. Tomorrow, perhaps many more cancers. Science continues to remind us that hope isn't just an emotion. It's innovation backed by research. What's your perspective on personalized cell therapies?  Could they become the future standard of cancer treatment? #CancerResearch #Immunotherapy #TILTherapy #Melanoma #CellTherapy #PrecisionMedicine #Oncology #HealthcareInnovation #MedicalBreakthrough #FutureOfMedicine

Complementary and alternative medicine (CAM) and delays in cancer care: a new systematic review and meta-analysis. A newly published online-first article in Nowotwory. Journal of Oncology examines whether the use of complementary and alternative medicine is associated with delays in cancer diagnosis and initiation of treatment. The analysis of five observational studies involving 1,287 patients found that CAM use was associated with higher odds of delayed cancer diagnosis (OR 2.12; 95% CI 1.59–2.83) and delayed initiation of treatment (OR 2.00; 95% CI 1.03–3.90). The findings underline the importance of proactive, non-judgmental communication about CAM use. Complementary approaches should not delay evidence-based cancer diagnosis or treatment. Read the full article on risky therapies that lead to delays in the diagnosis and treatment of cancer https://lnkd.in/dnvrNrH8

World Lung Cancer Day Two patients. Same lung cancer. Same treatment. One lived nearly a year and a half, the other barely five months. That gap is exactly what CHOSA Oncology exists to close. On this World Lung Cancer Day, we stand with patients, families, clinicians and researchers working toward one common goal: ensuring every patient receives the treatment most likely to benefit them.   For patients with lung cancer, every treatment decision matters - they simply do not have time for ineffective treatments. Selecting the right treatment from the very beginning can improve outcomes and spare patients unnecessary toxicity.   At CHOSA Oncology, we are developing a biomarker that helps identify which patients are most likely to benefit from platinum-based chemotherapy. Platinum remains the backbone of treatment for many patients with lung cancer, including in combination with today's PD-(L)1 immunotherapies. By bringing tumor biology into these treatment decisions, we aim to help clinicians identify the patients most likely to benefit from platinum-based therapy.   We believe that understanding the biology of each patient's tumor can help clinicians select treatment more precisely, avoid ineffective therapy, and ultimately improve patient outcomes.   A message from our Co-Founder & CEO, Peter Buhl Jensen: "After more than 35 years in oncology, I remain inspired by one simple ambition: to replace informed guesswork with biology whenever treatment decisions are made. Every patient's tumor is different, and our responsibility is to use that biology to guide treatment as precisely as possible. Better decisions lead to better treatment outcome, and that is what continues to drive our work every day." #WorldLungCancerDay #LungCancer #PrecisionOncology #PlatinDRP #Biomarkers #Oncology #PrecisionMedicine #Cisplatin #LifeSciences #HealthcareInnovation #IntelligentOncology

A vaccine targeting one of colorectal cancer’s most common mutations is showing early promise. In a Phase I trial, researchers combined a KRAS-targeted vaccine with two immunotherapies for 13 patients with advanced colorectal cancer. The treatment met its safety goals and triggered KRAS-specific immune responses in most patients. The results are still early, but they point to a possible new direction for cancers that often respond poorly to immunotherapy. Combining a cancer vaccine with two immunotherapies also requires coordinating various materials, samples, and trial activities. CRYOPDP specialises in clinical trial logistics, managing these movements between research teams, clinical sites and laboratories. Read more: https://lnkd.in/eg4uGNSs. #CRYOPDP #ClinicalTrials #CancerVaccines #KRAS #ColorectalCancer #Immunotherapy #ClinicalTrialLogistics #OncologyResearch #LifeSciences

An effective new treatment for metastatic prostate cancer is now available to a much larger group of people with the disease. The FDA has expanded its approval of Pluvicto® (¹⁷⁷Lu-PSMA-617) to be given in combination with hormonal therapy as an initial treatment for patients with metastatic prostate cancer, if a PET scan shows the cancer is positive for the PSMA protein. Pluvicto is a radioactive molecule that selectively seeks out and attaches to PSMA on the cancer cell surface. It delivers radiation that damages DNA and destroys the cancer cell. “This type of precision medicine has been a game changer for people whose prostate cancer has spread outside of the prostate,” says Dr. Michael Morris, a genitourinary medical oncologist at Memorial Sloan Kettering Cancer Center (MSK). The latest approval is based on results from a phase 3 clinical trial called PSMAddition. Dr. Morris was a key leader of the study in the U.S. Learn more about what this expanded approval means for people with metastatic prostate cancer: https://bit.ly/4bJ4W7f